HOB Biotech released its 2026 interim report on August 18, 2026. The company's total operating revenue was 196 million yuan, net profit attributable to the parent company was 16.6776 million yuan, and net cash inflow from operating activities was 37.2862 million yuan. The company's latest asset-liability ratio was 9.29%, gross margin was 60.34%, ROE was 2.01%, and diluted earnings per share was 0.27 yuan. The company's latest total asset turnover was 0.21 times, and inventory turnover was 0.73 times. The number of shareholders was 3,509, and the top ten shareholders held 48.9519 million shares, accounting for 77.07% of the total share capital.
HOB Biotech Group Corp LtdCompany released interim report with net profit of 16.68 million yuan, indicating financial performance.
